Sanofi begins Kevzara’s trial for Covid-19 outside US

30 March 2020 (Last Updated March 30th, 2020 11:11)

Sanofi has started a Phase II/III clinical trial of rheumatoid arthritis drug Kevzara (sarilumab) to treat patients hospitalised with severe Covid-19 infection outside of the US.

The first participant in the study, which is being conducted in Italy, Spain, Germany, France, Canada and Russia, has already been treated.

Sanofi’s partner, Regeneron Pharmaceuticals, is responsible for performing the study’s counterpart in the US, which commenced earlier this month.

Read the full article here